Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer

Abstract

The combination of CD47 blockade and macrophage activation by cabazitaxel synergizes to vastly enhance the elimination of TNBC cells. Our results show that targeting macrophages is a promising and effective strategy for TNBC treatment.